Actively Recruiting
Treatment and Prognosis of Patients With Chronic HBV Infection
Led by Xiangya Hospital of Central South University · Updated on 2022-05-26
500
Participants Needed
1
Research Sites
260 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Hepatitis B virus (HBV) infection is a major global health issue with 257 million chronically infected individuals. Of note, China has the largest population accounting for one third of the world's infected population. Approximately, about 300 000 people die each year due to the consequences of HBV. In 2016, the World Health Organization (WHO) proposed the goal for elimination of hepatitis B as public health threat by 2030 and China will be a major contributor towards this global goal. Currently, two approved therapeutic strategies are available including pegylated interferon (IFN) or nucleos (t) ide analogues (NA), which could suppress HBV replication and slow disease progression. Here, investigators hope to launch a cohort study to reveal the clinical features relating to therapeutic efficacy of antiviral therapy and the prognosis of patients with differential therapeutic strategies.
CONDITIONS
Official Title
Treatment and Prognosis of Patients With Chronic HBV Infection
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with evidence of chronic HBV infection
You will not qualify if you...
- Chronic liver injury mainly caused by other reasons, such as autoimmune diseases, alcohol, drugs and so on.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Department of Infectious Disease, Xiangya Hospital, Central South University
Changsha, Hunan, China, 410008
Actively Recruiting
Research Team
Y
Yan Huang
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here